from the intervention. This is an important consideration both from an ethical perspective (risk of the intervention without opportunity for benefit) and from a power/ sample size perspective. It would be surprising to me if more than 50% of the 60 patients the investigators intend to enroll would have moderate or severe pain at 6 weeks, even without an intervention. --The second area for further consideration is the study population. It is clear than not all musculoskeletal pain is alike. Low back pain has a much different clinical course than gout, which in turn is different from phalangeal fractures. I would like to see either more attempts to homogenize the study population or more explanation of why this isn't necessary. --Finally, there is very likely to be an association between adherence to the investigational medication regimen and clinical course. Patients who improve rapidly and completely may decide that they should no longer take the medication than patients who continue to suffer. Alternatively, patients who fail to improve may seek out alternative treatments in lieu of the investigational medication. Since adherence is the primary outcome of this pilot study, it would have been nice to have seen some thought given to this issue in the outcome assessment and analysis sections.
Other points: --Inclusion criteria: Rather than use a surrogate marker for moderate or severe pain (Pain >= 4), why not ask patients, "Is you pain mild, moderate, or severe?" --Inclusion criteria: The investigators are using a non-standard definition for chronic pain --Inclusion criteria: Wouldn't it be preferable to exclude any patient using any opioid rather than the more subjective criterion the investigators chose? Please explain your rationale.
--In the assessments section, there is mention of advancing the medication dosage. Please clarify.
--Acute pain relief assessment. Musculoskeletal pain typically varies depending on usage. When you ask for the 0-10 score, are you asking for worst score in the previous 24 hours or score at the time of the interview (when the patient is presumably in a position of comfort).
--The second sentence of the sample size section is missing a number. Also, you don't state what was considered to be a clinically meaningful change.
REVIEWER
Christina Abdel Shaheed University of Sydney, School of Public Health, Faculty of Medicine and Health REVIEW RETURNED 06-Aug-2018
GENERAL COMMENTS
This is an interesting study exploring the potential use of duloxetine in the prevention of chronic pain. Whilst this is an area that certainly warrants investigation I have some concerns about the proposed approach in this study.
Major comments:
The major concern I have is that the authors have grouped all acute musculoskeletal pain together, but the rationale for this is questionable. Do we know if all acute musculoskeletal pain behave in the same way? Would a better approach have been to choose a specific musculoskeletal condition e.g. acute low back pain or acute neck pain or acute knee pain and set some clear inclusion and exclusion criteria? The authors propose stratification based on traumatic/non traumatic pain, but the bigger issue, I feel, is that all acute MSK pain will be considered. At a minimum, stratification based on type of MSK pain should be carried out.
Minor comments:
The inclusion criteria "generally in good health" is non-specific.
Can you clarify what you mean by this, as it will also help the clinicians enrolling participants know who to consider. I would also recommend clearly defining pain duration in the inclusion criteriais this pain lasting < 6 weeks, < 3 months? This needs to be very clear.
Why are you looking at axial pain specifically? What is this significance of this for different types of musculoskeletal pain and how will it differ depending upon the location of the pain?
Why will you only look at opioid use as rescue drug? Could you also consider NSAIDs?
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 --The first is the important question of which patients with acute musculoskeletal pain will go on to develop chronic musculoskeletal pain. In Dr. McLean's MVC data, 70% of patients had any pain (including mild pain) at 6 weeks (PMID 24145211). In my center's acute LBP dataset, only 10-25% of ED patients go on to have moderate or severe LBP at three months (PMID 29089169, 28187918, 26501533) . Therefore, of the 60 patients that these investigators enroll, many will not have the opportunity to benefit from the intervention. This is an important consideration both from an ethical perspective (risk of the intervention without opportunity for benefit) and from a power/ sample size perspective. It would be surprising to me if more than 50% of the 60 patients the investigators intend to enroll would have moderate or severe pain at 6 weeks, even without an intervention.
We appreciate the first reviewer's body of work related to this problem and comments. To the reviewer's point, a substantial proportion of LBP patients (10-25%) have ongoing pain months after their initial episode. References above added. This is likely higher in patients with traumatic pain, as this also involves a psychological stressor (i.e., perceived life threatening event in the case of MVCs) in addition to the physical injury/ tissue trauma (PMID 28030471). As this is a pilot feasibility study, the primary outcome is tolerability and this study is not powered to detect chronic pain outcomes. Other outcomes of interest (e.g., 6 week pain) are secondary outcomes. Based on our preliminary work, we expect that at least 50% will having ongoing pain 6 weeks post-ED visit. We have selected for patients with moderate to severe pain at baseline as this is a strong predictor of persistent pain. This was clarified in the "Introduction" section of the protocol.
--The second area for further consideration is the study population. It is clear than not all musculoskeletal pain is alike. Low back pain has a much different clinical course than gout, which in turn is different from phalangeal fractures. I would like to see either more attempts to homogenize the study population or more explanation of why this isn't necessary.
We completely agree with this statement and will clarify the text. We have clarified the text ("Study Protocol" section") to highlight that patients only with axial musculoskeletal pain (that is pain in the back, neck or shoulders) will be recruited into the study. Pain in these regions is at increased risk of persistent or chronic pain development.
--Finally, there is very likely to be an association between adherence to the investigational medication regimen and clinical course. Patients who improve rapidly and completely may decide that they should no longer take the medication than patients who continue to suffer. Alternatively, patients who fail to improve may seek out alternative treatments in lieu of the investigational medication. Since adherence is the primary outcome of this pilot study, it would have been nice to have seen some thought given to this issue in the outcome assessment and analysis sections.
Tolerability is the primary outcome. We have redefined tolerability based on the proportion of participants reporting adverse events and the proportion of participants dropping out due to adverse events. We have clarified the analysis section to include that the analysis for the secondary outcomes is an intention to treat analysis. In addition, we will measure through patient self-report other treatments received during the intervention and post-intervention periods. This may be informative to future studies and interventions, in particular examination of treatment responders and non-responders.
Other points: --Inclusion criteria: Rather than use a surrogate marker for moderate or severe pain (Pain >= 4), why not ask patients, "Is you pain mild, moderate, or severe?"
Both are options to self-report pain. The numerical rating score was chosen as this is a commonly used method to assess for pain in the clinical setting (PMID 12563698).
--Inclusion criteria: The investigators are using a non-standard definition for chronic pain We agree. The inclusion criteria have been amended.
--Inclusion criteria: Wouldn't it be preferable to exclude any patient using any opioid rather than the more subjective criterion the investigators chose? Please explain your rationale.
These criteria have been rephrased.
This an error and was removed.
We have clarified: Patients reporting moderate to severe pain at any time during the ED visit (clinical care or during the interview) are eligible.
We have amended / clarified this section to reflect that the tolerability endpoints are the primary outcomes and the basis for the sample size calculation.
Reviewer: 2
We appreciate this comment and agree. Please see clarifications as noted above.
The inclusion criteria "generally in good health" is non-specific. Can you clarify what you mean by this, as it will also help the clinicians enrolling participants know who to consider.
We agree this is a vague term and has been be removed. Participant health is covered by the exclusion criteria.
I would also recommend clearly defining pain duration in the inclusion criteria -is this pain lasting < 6 weeks, < 3 months? This needs to be very clear.
Eligible pain is pain lasting 7 days or less. Chronic pain exclusion is defined more clearly.
Take from original proposal, increased risk of chronic pain
Will will evaluate opioids and NSAIDs. We will also assess other treatments received (e.g., PT). 
VERSION 2 -REVIEW REVIEWER

GENERAL COMMENTS
Thank you for the clarifications. Is the larger planned RCT also restricting pain duration to < 7 days? Will you potentially be missing those people who are at greatest risk of developing chronic pain? I think some justification for the 7-day inclusion criteria is required as there are some people who will argue you are likely to get a positive result overall for these patients but are missing an opportunity to intervene for those people who require it the most. We appreciate the reviewer's comments and thank them for taking the time to review this manuscript.
VERSION 2 -AUTHOR RESPONSE
Reviewer: 2 Reviewer Name: Christina Abdel Shaheed Institution and Country: University of Sydney, Australia Please state any competing interests or state 'None declared': NA Please leave your comments for the authors below Thank you for the clarifications. Is the larger planned RCT also restricting pain duration to < 7 days? Will you potentially be missing those people who are at greatest risk of developing chronic pain? I think some justification for the 7-day inclusion criteria is required as there are some people who will argue you are likely to get a positive result overall for these patients but are missing an opportunity to intervene for those people who require it the most.
We thank the reviewer for their comments and insight. A shorter duration of acute pain (<7 days) was chosen for two reasons: first ED patients with acute pain, are likely to present early in the course of pain and second, a hypothesized mechanism by which duloxetine may prevent chronic pain (descending modulation) may be dependent on pain duration (Ref PMID: 22102847). If this preliminary study is effective, subsequent studies may examine different durations of pain intensity as a moderator of treatment effect. We have updated the manuscript to include the above rationale.
